

From: dph.immunizations@ct.gov <noreply@everbridge.net>

Sent: Tuesday, August 27, 2024 9:20 AM

Subject: 2024-2025 COVID-19 Vaccine Update and CVP Availability



[Please click here to acknowledge receipt of this message](#)

August 27, 2024

This communication is being sent to all key contacts at provider organizations enrolled in the CT Vaccine Program (CVP). Please feel free to share it with others in your organization who may benefit from the update. Note that all our communications are archived on our web site [here](#).

Dear CVP providers,

On August 22, 2024, the U.S. Food and Drug Administration ([FDA](#)) [approved and authorized the 2024-2025 mRNA COVID-19 vaccines](#) formulated to target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death.

It is recommended that **everyone ages 6 months and older get the 2024–2025 COVID-19 vaccine. This includes people who have received a COVID-19 vaccine before and people who have had natural infection.** The minimum interval from a previous COVID-19 vaccine dose is 8 weeks. People who recently had SARS-CoV-2 infection may consider delaying a COVID-19 vaccine dose by 3 months from symptom onset or positive test (if infection was asymptomatic). The revised interim clinical considerations for the use of COVID-19 vaccines can be found [here](#).

2023–2024 COVID-19 Vaccines

In addition, the FDA has deauthorized all Pfizer-BioNTech and Moderna 2023–2024 COVID-19 vaccines. While the Novavax 2023–24 COVID-19 vaccine remains authorized, it is no longer available, and all doses have expired. If your clinic has any deauthorized or expired COVID-19 vaccines from the 2023–2024 season, please remove all doses from inventory to prevent any accidental administration.

All state supplied deauthorized or expired COVID-19 doses should be returned to McKesson similarly to other non-viable CVP vaccines. For assistance on how to complete a return in CT WiZ, please click [here](#).

Ordering CVP 2024–2025 COVID-19 Vaccines:

With this new FDA approval and authorization, the 2024–2025 COVID-19 vaccines will be available to order through the CVP for use in all children aged 6 months through 18 years. We anticipate sufficient supply of COVID-19 vaccines throughout the season and will be able to fulfill provider orders.

Restitution will not be required for COVID-19 vaccines if a provider is unable to utilize all doses prior to expiration. Therefore, providers should only place orders based on clinic needs and place orders as often as necessary. All orders should be placed directly in CT WiZ. For assistance in placing an order, please visit our CT WiZ [training website](#) or submit a [help desk ticket](#) (Immunizations-Clinic Administration-CT WiZ Training and Inventory Support).

Currently the CVP has Pfizer-BioNTech doses available to order and expects to have Moderna doses later this week. Novavax (2024–2025) will be available at a future date; the CVP will send out a communication once those doses are available to order.

Manufacturer	Presentation	Unit of Sale NDC
Pfizer Inc.	12y+; PRE-FILLED SINGLE DOSE SYRINGE; 10pk	00069-2432-10
Pfizer Inc.	Pediatric 5y-11y; SINGLE DOSE VIAL; 10pk	59267-4438-02
Pfizer Inc.	Pediatric 6m-4y; 3 DOSE MULTIDOSE VIAL; 10pk*	59267-4426-02
ModernaTX Inc.**	12y+; PRE-FILLED SINGLE DOSE SYRINGE; 10pk	80777-0110-93
ModernaTX Inc.**	Pediatric 6m-11y; PRE-FILLED SINGLE DOSE SYRINGE; 10pk	80777-0291-80

*Shipping for Pfizer’s pediatric presentation for children 6m–4y is expected to begin September 4, 2024.

**Ordering for the updated Moderna COVID-19 vaccines listed above are anticipated to be later this week.

As always, thank you for your continued support and effort to support vaccination.

For the CT DPH Immunization Program, visit: [Contact Us](#)

If you would like to subscribe to receive these communications, please complete [this form](#). If you would like to unsubscribe from receiving these communications, please complete [this form](#).